Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in---

Primary tabs

field_vote: 
Average: 8 (1 vote)
Publication type: 
Therapeutic intervention: 
Therapeutic Substance(s): 
References: 

Cancer Chemother Pharmacol. 2007 Aug;60(3):351-6. Epub 2006 Nov 17.
 
Biweekly
oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by
metronomic chemotherapy with tegafur/uracil in pretreated metastatic
colorectal cancer.

Lin PC, Chen WS, Chao TC, Yang SH, Tiu CM, Liu JH.Division
of Medical Oncology, Taipei Veterans General Hospital and National
Yang-Ming University, No. 201, Shi-Pai Rd., Sec. 2, Taipei 112, Taiwan,
ROC.
PURPOSE: Metronomic chemotherapy, at a minimally toxic dose
and with a frequent schedule, is a potentially novel approach to the
control of advanced cancer disease via a different mechanism from
maximum tolerable doses chemotherapy. Taking advantage of the potential
effectiveness of metronomic therapy, tegafur/uracil (UFT) was
incorporated into an oxaliplation/infusioanl fluouracil
(5-FU)/leucovorin (LV) protocol in this study. The primary endpoints
were response rate, time to progression (TTP) and safety profile in
5-FU-pretreated metastatic colorectal cancers (CRCs).
 
PATIENTS AND
METHODS:
Twenty-eight patients with metastatic CRCs resistant or
refractory to 5-FU/LV were enrolled. Chemotherapy was administrated
every 2 weeks sequentially with 2-h infusion of oxaliplatin (85 mg/m2)
and LV (200 mg/m2), intravenous bolus 5-FU (400 mg/m2), 22-h infusion
of 5-FU (600 mg/m2) on day 1 and then followed by 10-day daily oral UFT
(200 mg/m2)/LV (30 mg/m2).
 
RESULTS: Partial response was seen in ten
(35.7%) patients. The median TTP was 5.2 (95% CI: 4.16-6.31) months and
the median overall survival was 13.4 (95% CI: 6.39-20.5) months. No
grade 3 toxicities above 5% according to National Cancer
Institute-Common Toxicity Criteria (NCI-CTC) occurred except sensory
neuropathy (10.7%). No grade 4 toxicity, treatment-related mortality or
hand-foot syndrome was found.
 
CONCLUSIONS: This study protocol with
favorable toxicity profile is thus promisingly effective against
5-FU-pretreated metastatic CRCs. Given the present experience, an
evaluation of the regimen as front-line treatment of metastatic CRC is
planned.